bohemine has been researched along with cyc 202 in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (10.00) | 18.2507 |
2000's | 6 (60.00) | 29.6817 |
2010's | 3 (30.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Havlícek, L; Krystof, V; Kuzma, M; Lenobel, R; Strnad, M | 1 |
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
Bravo-Altamirano, K; DeStefino, NR; Liang, M; Mazzarisi, CM; Meriney, SD; Olszewski, RA; Rensch, G; Swanson, L; Tarr, TB; Valdomir, G; Wilson, GM; Wipf, P | 1 |
Bazgier, V; Berka, K; Gucký, T; Havlíček, L; Jaffe, CL; Jorda, R; Kryštof, V; Nasereddin, A; Popa, A; Popa, I; Řezníčková, E; Strnad, M; Zatloukal, M | 1 |
Binarová, P; Bögre, L; Dolezel, J; Draber, P; Heberle-Bors, E; Strnad, M | 1 |
Fischer, PM; Goddard, PM; Lane, DP; Nutley, BP; Raynaud, FI; Workman, P | 1 |
Adona, PR; Lima Verde Leal, C | 1 |
Barrie, SE; Brunton, L; Clarke, SJ; Eccles, S; Fischer, PM; Garrett, MD; Kelland, LR; Lane, DP; McClue, S; Raynaud, FI; Rogers, P; Valenti, M; Walton, MI; Whittaker, SR; Workman, P | 1 |
An, R; Hagiya, Y; Ishikawa, T; Li, S; Saito, H; Tamura, A; Tokushima, D | 1 |
Cwiertka, K; Dzubak, P; Hajduch, M; Korinkova, G; Paprskarova, M | 1 |
10 other study(ies) available for bohemine and cyc 202
Article | Year |
---|---|
Synthesis and biological activity of olomoucine II.
Topics: Antineoplastic Agents; CDC2 Protein Kinase; CDC28 Protein Kinase, S cerevisiae; Cell Survival; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Kinetin; Purines; Roscovitine; Structure-Activity Relationship; Tumor Cells, Cultured | 2002 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
Synthesis and biological evaluation of a selective N- and p/q-type calcium channel agonist.
Topics: | 2012 |
2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro.
Topics: Antiprotozoal Agents; Binding Sites; Leishmania donovani; Leishmania major; Models, Molecular; Molecular Structure; Protein Binding; Protein Conformation; Proto-Oncogene Proteins c-crk; Purines; Structure-Activity Relationship | 2015 |
Treatment of Vicia faba root tip cells with specific inhibitors to cyclin-dependent kinases leads to abnormal spindle formation.
Topics: Calcium-Calmodulin-Dependent Protein Kinases; CDC2 Protein Kinase; Cell Cycle; Cyclin A; Cyclin B; Enzyme Inhibitors; Fabaceae; Meristem; Microtubules; Plant Roots; Plants, Medicinal; Protein Kinases; Purines; Roscovitine; Spindle Apparatus; Transcription, Genetic | 1998 |
Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis.
Topics: Animals; Area Under Curve; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Free Radicals; Gene Library; Mice; Mice, Inbred BALB C; Models, Chemical; Neoplasms; Purines; Roscovitine; Structure-Activity Relationship; Time Factors | 2004 |
Meiotic inhibition with different cyclin-dependent kinase inhibitors in bovine oocytes and its effects on maturation and embryo development.
Topics: 4-Butyrolactone; Animals; Cattle; Cyclin-Dependent Kinases; Embryo, Mammalian; Meiosis; Oocytes; Purines; Roscovitine | 2004 |
In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Topics: Animals; Area Under Curve; Blotting, Western; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Enzyme Inhibitors; Female; HCT116 Cells; Humans; Inhibitory Concentration 50; Kinetin; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Phosphorylation; Purines; Recombinant Proteins; Retinoblastoma Protein; Roscovitine; Time Factors; Tissue Distribution; Xenograft Model Antitumor Assays | 2005 |
Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line; Cell Membrane; Cell Survival; Chlorophyll; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Hematoporphyrins; Humans; Kinetin; Models, Molecular; Molecular Conformation; Molecular Structure; Neoplasm Proteins; Photosensitizing Agents; Protein Kinase Inhibitors; Purines; Quantitative Structure-Activity Relationship; Quinazolines; Roscovitine; Spodoptera; Transfection | 2009 |
The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors.
Topics: Adenocarcinoma; Apoptosis; Blotting, Western; Cell Cycle; Cyclin-Dependent Kinases; Flow Cytometry; Humans; Kinetin; Lung Neoplasms; Protein Kinase Inhibitors; Purines; Radiation-Sensitizing Agents; Roscovitine; Tumor Cells, Cultured; X-Rays | 2010 |